An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

Falsified medicines are fakes that get into the supply chain, often via the Internet. These could be tablets or injectables that have the wrong amount of the right drug, with a dose that is too low or ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

A | THERE’S NO QUESTION THAT THE COST CURVE MUST COME DOWN FOR DRUG DEVELOPMENT TO REMAIN ECONOMICALLY VIABLE. Fortunately, Congress and the FDA have recognized the problem. Pursuant to new ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...